Previous eQTL analysis in peripheral blood consistently suggested that ZFP90, rather than CDH1 or CDH3, is the most likely target of the16q22.1 genetic variation associated with increased CRC risk [17]. The gene discussed is CDH3; the disease is colorectal carcinoma.